DOCSLIB.ORG

Smith & Kenner Pharmaceuticals Pvt. Ltd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Smith & Kenner Pharmaceuticals Pvt. Ltd SMITH & KENNER PHARMACEUTICALS PVT. LTD. 16-2-738/F/4, ASMANGADH, MALAKPET, HYDERABAD, INDIA. Website:- www.smithkenner.com Emails:[email protected],[email protected] ANTI HIV PRODUCTS 1 LAMIVUDINE TABLETS Each uncoated tablet contains: Lamivudine IP 150mg 2 EFFAVIRENZ CAPSULES Each hard gelatin capsules contains: Effavirenz IP 200mg 3 INDINAVIR CAPSULES Each hard gelatin capsules contains: Indinavir IP 400mg 4 NEVIRAPINE ORAL SUSPENSION Each 5ml contains: Nevirapine IP 50mg 5 STAVUDINE,LAMIVUDINE,NEVIRAPINE TABLETS Each uncoated tablet contains: Stavudine IP 40mg Lamivudine IP 150mg Nevirapine IP 200mg 6 ZIDOVUDINE,LAMIVUDINE,NEVIRAPINE TABLETS Each uncoated tablet contains: Zidovudine IP 300mg Lamivudine IP 150mg Nevirapine IP 200mg SMITH & KENNER PHARMACEUTICALS PVT. LTD. 16-2-738/F/4, ASMANGADH, MALAKPET, HYDERABAD, INDIA. Website:- www.smithkenner.com Emails:[email protected],[email protected] 7 TENOFAVIR TABLETS Each uncoated tablet contains: Tenofavir disproxil fumarate IP 300mg 8 LAMIVUDINE,ZIDOVUDINE TABLETS Each uncoated tablet contains: Lamivudine IP 150mg Zidovudine IP 300mg 9 EFFAVIRENZ TABLETS Each film coated tablet contains: Effavirenz IP 600mg EFFAVIRENZ,EMTRICITABINE,TENOFAVIR 10 TABLETS Each tablet contains: Effavirenz IP 600mg Emtricitabine IP 200mg Tenofavir IP 300mg 11 TENOFAVIR,EMTRICITABINE TABLETS Each film coated tablet contains: Tenofavir disproxil fumerate IP 300mg Emtricitabine IP 200mg 12 LOPINAVIR,RITONAVIR TABLETS Each tablet contains: Lopinavir IP 200mg Ritonavir IP 50mg SMITH & KENNER PHARMACEUTICALS PVT. LTD. 16-2-738/F/4, ASMANGADH, MALAKPET, HYDERABAD, INDIA. Website:- www.smithkenner.com Emails:[email protected],[email protected] 13 RITONAVIR CAPSULES Each film coated tablet contains: Ritonavir IP/BP 100mg Colour : Titanium dioxide 14 OSELTAMIVIR PHOSPHATE CAPSULES Each hard gelatine capsules contains: Oseltamivir phosphate 98.5mg equivalent to oseltamivir 75mg 15 ZIDOVUDINE CAPSULES (FOR EXPORT) Each capsule contains Zidovudine BP 100mg 16. TENOFAVIR ALFANAMIDE TABLETS (FOR EXPORT) Each tablet contains: Tenofavir alfanamide 25mg 17. Zidovudine Syrup (Dometsic/Export) Each ml Contains Zidovudine IP/BP 10mg 18. ADEFOVIR DIPIVOXIL TABLETS (FOR EXPORT) Each tablet contains: Adefovir dipivoxil BP 10mg 19. DARUNAVIR TABLETS (For Export ) Each tablet contains: Darunavir 300mg SMITH & KENNER PHARMACEUTICALS PVT. LTD. 16-2-738/F/4, ASMANGADH, MALAKPET, HYDERABAD, INDIA. Website:- www.smithkenner.com Emails:[email protected],[email protected] 20. LAMIVUDINE TABLETS Each uncoated tablet contains: Lamivudine IP 100mg SMITH & KENNER PHARMACEUTICALS PVT. LTD. 16-2-738/F/4, ASMANGADH, MALAKPET, HYDERABAD, INDIA. Website:- www.smithkenner.com Emails:[email protected],[email protected] UNDER FORM-25 ONDANSETRON HCL ORALLY DISINTEGRATING 1 TABLETS Each uncoated tablet contains: Ondansetron Hcl IP 8mg ONDANSETRON HCL ORALLY DISINTEGRATING 2 TABLETS Each uncoated tablet contains: Ondansetron Hcl IP 4mg 3 ACETAZOLAMIDE TABLETS Each film coated tablet contains: Acetazolamide IP 250mg 4 OLMESARTAN MEDOXOMIL TABLETS Each film coated tablet contains: Olmesartan medoxomil 20mg Colour: Titanium dioxide 5 OLMESARTAN MEDOXOMIL TABLETS Each film coated tablet contains: Olmesartan medoxomil 40mg Colour : Titanium dioxide 6 BICALUTAMIDE TABLETS Each tablet contains: Bicalutamide IP 50mg SMITH & KENNER PHARMACEUTICALS PVT. LTD. 16-2-738/F/4, ASMANGADH, MALAKPET, HYDERABAD, INDIA. Website:- www.smithkenner.com Emails:[email protected],[email protected] 7 BISACODYL TABLETS Each tablet contains: Bisacodyl IP 5mg 8 BROMOCRIPTINE MISELAYTE TABLETS Each uncoated tablet contains: Bromocriptine miselayte IP 2.87mg (Equal to 2.5mg of bromocriptine base) 9 FEBUXOSTAT TABLETS Each film coated tablet contains: Febuxostat 40mg Excipients Q.S Colour: Titanium dioxide 10 FEBUXOSTAT TABLETS Each film coated tablet contains: Febuxostat 80mg Excipients Q.S 11 CEFADROXIL TABLETS Each uncoated tablet contains: Cefadroxil anhydrous IP Equivalent to Cefadroxil 500mg 12 SEVLAMER CARBONATE TABLETS Each film coated tablet contains: Sevlamer carbonate 400mg Excipients Q.S Colour : Titanium dioxide SMITH & KENNER PHARMACEUTICALS PVT. LTD. 16-2-738/F/4, ASMANGADH, MALAKPET, HYDERABAD, INDIA. Website:- www.smithkenner.com Emails:[email protected],[email protected] 13 CEFIXIME TABLETS Each film coated tablet contains: Cefixime (as trihydrate) Equivalent to anhydrous cefixime IP 100mg Colour: Titanium dioxide 14 ALPRAZOLAM TABLETS I.P Each uncoated tablet contains: Alprazolam IP 0.5mg 15 ALPRAZOLAM TABLETS I.P Each uncoated tablet contains: Alprazolam IP 1mg 16 CINNARIZINE TABLETS Each uncoated tablet contains: Cinnarizine IP 25mg Colour : Tatrazine 17 IBUPROFEN, PARACETAMOL,DL-METHOININE TABLETS I.P Each uncoated tablet contains: Ibuprofen IP 400mg Paracetamol IP 325mg DL-Methionine USP 32.5mg 18 ESCITALOPRAM TABLETS Each film coated tablet contains: Escitalopram Oxalate IP Equivalent to excitalopram 10mg SMITH & KENNER PHARMACEUTICALS PVT. LTD. 16-2-738/F/4, ASMANGADH, MALAKPET, HYDERABAD, INDIA. Website:- www.smithkenner.com Emails:[email protected],[email protected] 19 FLUCANAZOLE TABLETS Each uncoated tablet contains; Flucanazole IP 200mg Excipients Q.S 20 FLUVOXIMINE TABLETS Each film coated tablet contains: Fluvoximine maleate IP 50mg Excipients : Q.S Colour : Yellow Oxide of Iron 21 PARACETAMOL,CHLORZOXAZONE,DICLOF ENAC POTASSIUM TABLETS I.P Each tablet contains: Paracetamol IP 325mg Chlorzoxazone USP 250mg Diclofenac Potassium BP 50mg 22 LEVOCETRIZINE HYDROCHLORIDE , MONTELUKAST SODIUM TABLETS Each uncoated tablet contains: Levocetrizine Hcl IP 5mg Montelukast sodium IP Equivalent to montelukast 10mg Colour : Quinaline yellow lake 23 PANTAPRAZOLE TABLETS I.P Each enteric coated tablet contains: Pantaprazole Sodium IP Equivalent to Pantaprazole 40mg SMITH & KENNER PHARMACEUTICALS PVT. LTD. 16-2-738/F/4, ASMANGADH, MALAKPET, HYDERABAD, INDIA. Website:- www.smithkenner.com Emails:[email protected],[email protected] NIMESULIDE TABLETS 24 Each uncoated tablet contains: Nimesulide IP 100mg 25 CARBAMEZIPINE TABLETS I.P Each tablet contains: Carbamezipine IP 200mg 26 MEFENAMIC ACID TABLETS Each uncoated tablet contains: Mefenamic acid IP 500mg Excipients : Q.S 27 ALBENDAZOLE TABLETS Each uncoated tablet contains: Albendazole IP 400mg 28 MEFLOQUINE TABLETS Each uncoated tablets: Mefloquine Hcl IP Equivalent to Mefloquine 250mg 29 NEBIVILOL TABLETS Each uncoated tablet contains: Nebivilol hcl IP Equivalent to Nebivilol 5mg 30 NICOUMALONE TABLETS Each uncoated tablet contains: Nicoumalone IP 1mg SMITH & KENNER PHARMACEUTICALS PVT. LTD. 16-2-738/F/4, ASMANGADH, MALAKPET, HYDERABAD, INDIA. Website:- www.smithkenner.com Emails:[email protected],[email protected] 31 OFLOXACIN TABLETS I.P Each film coated tablet contains: Ofloxacin IP 100mg Colour: Ferric Oxide red 32 OFLOXACIN TABLETS I.P Each film coated tablet contains: Ofloxacin IP 200mg Colour: Ferric Oxide red 33 OLANZAPINE TABLETS Each film coated tablet contains: Olanzapine IP 10mg Colour: Titanium dioxide DICLOFENAC SODIUM, PARACETAMOL TABLETS 34 Each uncoated tablet contains: Diclofenac Sodium IP 50mg Paracetamol IP 325mg 35 OXYBUTYNIN CHLORIDE TABLETS Each uncoated tablet contains: Oxybutynin chloride BP 2.5mg Colour: Lake of Indigo Carmine 36 RISPIRODINE TABLETS Each uncoated tablet contains: Rispirodine BP 4mg SMITH & KENNER PHARMACEUTICALS PVT. LTD. 16-2-738/F/4, ASMANGADH, MALAKPET, HYDERABAD, INDIA. Website:- www.smithkenner.com Emails:[email protected],[email protected] 37 RIBAVIRIN CAPSULES Each capsule contains: Ribavirin IP 200mg 38 ROSUVASTATIN TABLETS Each film coated tablet contains: Rosuvastatin IP Equivalent to rosuvastatin 10mg Colour : Titanium dioxide 39 SERTALINE HCL TABLETS Each tablet contains: Sertaline hcl IP Equivalent to Sertaline 50mg 40 SERTALINE HCL TABLETS Each tablet contains: Sertaline hcl IP Equivalent to Sertaline 25mg 41 SOFOSBUVIR TABLETS Each film coated tablet contains Sofosbuvir 400mg Colour: Red oxide of Iron & Titanium dioxide PARACETAMOL,ACECLOFENAC SODIUM TABLETS 42 I.P Each uncoated tablet contains: Aceclofenac IP 100mg Paracetamol IP 325mg SMITH & KENNER PHARMACEUTICALS PVT. LTD. 16-2-738/F/4, ASMANGADH, MALAKPET, HYDERABAD, INDIA. Website:- www.smithkenner.com Emails:[email protected],[email protected] 43 TACROLIMUS CAPSULES Each hard gelatin capsule contains: Tacrolimus IP 0.5mg Colour: Approved colour used in empty capsule shell 44 TACROLIMUS CAPSULES Each hard gelatin capsule contains: Tacrolimus IP 1mg Colour: Approved colour used in empty capsule shell 45 URSODEOXYCHOLIC ACID TABLETS Each uncoated tablet contains: Ursodeoxycholic IP 150mg 46 VERAPAMIL TABLETS Each film coated tablet contains: Verapamil hcl IP 40mg Colour: Titanium dioxide 47 CARBAMEZIPINE TABLET I.P Each tablet contains: Carbamezepine IP 400mg 48 VOGLIBOSE TABLETS Each uncoated tablet contains: Voglibose IP 0.2mg Colour: Yellow Oxide of Iron SMITH & KENNER PHARMACEUTICALS PVT. LTD. 16-2-738/F/4, ASMANGADH, MALAKPET, HYDERABAD, INDIA. Website:- www.smithkenner.com Emails:[email protected],[email protected] 49 VOGLIBOSE TABLETS Each uncoated tablet contains: Voglibose IP 0.3mg Colour: Yellow Oxide of Iron 50 DICYCLOMINE HCL &PARACETAMOL TABLETS Each uncoated tablet contains: Dicyclomine hydrochloride IP 20mg Paracetamol IP 325mg 51 SODIUM DICHLOROISOCYNURATE TABLETS Each uncoated tablet contains: Sodium dichloroisocynurate Available Chlorine
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,227,427 B2 Coracci Neto Et Al
    USOO8227427B2 (12) United States Patent (10) Patent No.: US 8,227,427 B2 Coracci Neto et al. (45) Date of Patent: Jul. 24, 2012 (54) VETERINARIAN COMPOSITION (52) US. Cl. ........................................ .. 514/27; 514/368 COMPRISING AN ORGANIC SALT 0F (58) Field of Classi?cation Search ................. .. 513/71; LEVAMISOLE IN COMBINATION WITH AT 548/155; 514/27, 368 LEAST ONE AVERMECTIN AND/OR See application ?le for complete search history. MILBEMYCIN (75) Inventors: Dolivar Coracci Neto, Sertaozinho (56) References Cited (BR); Nelson Henriques Fernandes Filho, Jaboticabal (BR); Ricardo da FOREIGN PATENT DOCUMENTS Silva Sercheli, Jaboticabal (BR) BR PI0505716 A 9/2007 GB 2150024 A 6/1985 (73) Assignee: NPA—Nucleo de Pesquisas Aplicadas WO 00/74489 A1 12/2000 Ltda., Jaboticabal (BR) WO 2004/009080 A1 1/2004 OTHER PUBLICATIONS ( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 International Search Report. U.S.C. 154(b) by 575 days. Analytical Report Characterization of Pharmaceutical Input Aurixazol (Feb. 20, 2010). (21) App1.No.: 12/097,683 Primary Examiner * Elli Peselev (22) PCT Filed: Dec. 18, 2006 (74) Attorney, Agent, or Firm * Laurence P. Colton; Smith Risley Tempel Santos LLC (86) PCT No.: PCT/BR2006/000282 § 371 (0X1)’ (57) ABSTRACT (2), (4) Date: Nov. 3, 2008 Veterinarian composition comprising an organic salt of (87) PCT Pub. No.: WO2007/068073 levamisole in combination With at least one avermectin and/ or milbemycin. A veterinarian formulation comprising of organ PCT Pub. Date: Jun. 21, 2007 ics salts of levamisole, more speci?cally to the levamisole salt of 2,6-diiodo-4-nitrophenol and the levamisole salt of 4-hy (65) Prior Publication Data droxy-3-iodo-5-nitrobenzonitrile With avermectins and mil US 2009/0075918 A1 Mar.
    [Show full text]
  • Bulletin Leading the Fight Against Heartworm Disease
    BULLETIN LEADING THE FIGHT AGAINST HEARTWORM DISEASE SEPTEMBER HEARTWORM 2017 Q&A VOLUME 44 No. 3 Heartworm History: In What Year Was Heartworm First INSIDE THIS ISSUE Treated? Page 4 From the President Page 8 Research Update Abstracts from the Literature Page 14 Heartworm Hotline: Role of Heat Treatment in Diagnostics Page 19 NEW! Best Practices: Minimizing Heartworm Transmission in Relocated Dogs uestions from members, prac- published in the 1998 AHS Symposium 1 titioners, technicians, and the Proceedings. Dr. Roncalli wrote, “The Page 21 Qgeneral public are often submit- first trial to assess the efficacy of a Welcome Our New AHS ted to the American Heartworm Society microfilaricide (natrium antimonyl tar- Student Liaisons (AHS) via our website. Two of our AHS trate) was conducted some 70 years Board members, Dr. John W.McCall and ago (1927) in Japan by S. Itagaki and R. Page 25 Dr. Tom Nelson, provided the resources Makino.2 Fuadin (stibophen), a trivalent In the News: Surgeons to answer this question: In What Year antimony compound, was tested, intra- Remove a Heartworm from Was Heartworm First Treated? venously, as a microfilaricide by Popescu the Femoral Artery of a Cat The first efforts to treat canine heart- in 1933 in Romania and by W.H. Wright worm disease date back to the 1920s. Dr. and P.C. Underwood in 1934 in the USA. Page 26 Nelson referenced a review article by Dr. In 1949, I.C. Mark evaluated its use Quarterly Update Raffaele Roncalli, “Tracing the History of intraperitoneally.” What’s New From AHS? Heartworms: A 400 Year Perspective,” Continues on page 7 American Heartworm Society / PO Box 8266, Wilmington, DE 19803-8266 Become an American Heartworm Society www.heartwormsociety.org / [email protected] fan on Facebook! Follow us on Twitter! OUR GENEROUS SPONSORS PLATINUM LEVEL PO Box 8266 Wilmington, DE 19803-8266 [email protected] www.heartwormsociety.org Mission Statement The mission of the American Heartworm Society is to lead the vet- erinary profession and the public in the understanding of heartworm disease.
    [Show full text]
  • Baylisascariasis
    Baylisascariasis Importance Baylisascaris procyonis, an intestinal nematode of raccoons, can cause severe neurological and ocular signs when its larvae migrate in humans, other mammals and birds. Although clinical cases seem to be rare in people, most reported cases have been Last Updated: December 2013 serious and difficult to treat. Severe disease has also been reported in other mammals and birds. Other species of Baylisascaris, particularly B. melis of European badgers and B. columnaris of skunks, can also cause neural and ocular larva migrans in animals, and are potential human pathogens. Etiology Baylisascariasis is caused by intestinal nematodes (family Ascarididae) in the genus Baylisascaris. The three most pathogenic species are Baylisascaris procyonis, B. melis and B. columnaris. The larvae of these three species can cause extensive damage in intermediate/paratenic hosts: they migrate extensively, continue to grow considerably within these hosts, and sometimes invade the CNS or the eye. Their larvae are very similar in appearance, which can make it very difficult to identify the causative agent in some clinical cases. Other species of Baylisascaris including B. transfuga, B. devos, B. schroeder and B. tasmaniensis may also cause larva migrans. In general, the latter organisms are smaller and tend to invade the muscles, intestines and mesentery; however, B. transfuga has been shown to cause ocular and neural larva migrans in some animals. Species Affected Raccoons (Procyon lotor) are usually the definitive hosts for B. procyonis. Other species known to serve as definitive hosts include dogs (which can be both definitive and intermediate hosts) and kinkajous. Coatimundis and ringtails, which are closely related to kinkajous, might also be able to harbor B.
    [Show full text]
  • Computational Studies of Drug Repurposing Targeting P-Glycoprotein Mediated Multidrug-Resistance Phenotypes in Agents of Neglect
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.12.147926; this version posted June 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Computational studies of drug repurposing targeting P- glycoprotein mediated multidrug-resistance phenotypes in agents of neglected tropical diseases Nivedita Jaishankar 1, Sangeetha Muthamilselvan 2, Ashok Palaniappan 1,2* 1 Department of Biotechnology, Sri Venkateswara College of Engineering, Post Bag No. 1, Pennalur, Sriperumbudur Tk 602117. India 2 Department of Bioinformatics, School of Chemical and BioTechnology, SASTRA Deemed University, Thanjavur 613401. India * Corresponding author: [email protected] ABSTRACT Mammalian ABCB1 P-glycoprotein is an ATP- dependent efflux pump with broad substrate specificity associated with cellular drug resistance. Homologous to this role in mammalian biology, the P-glycoprotein of agents of neglected tropical diseases (NTDs) mediates the emergence of multidrug- resistance phenotypes. The clinical and socioeconomic implications of NTDs are exacerbated by the lack of research interest among Big Pharma for treating such conditions. This work aims to characterise P-gp homologues in certain agents of key NTDs, namely (1) Protozoa: Leishmania major, Trypanosoma cruzi; (2) Helminths: Onchocerca volvulus, Schistosoma mansoni. PSI-BLAST searches against the genome of each of these organisms confirmed the presence of P-gp homologues. Each homologue was aligned against five P- gp sequences of known structure, to identify the most suitable template based on sequence homology, phylogenetic nearest neighbor, and query coverage.
    [Show full text]
  • USP Reference Standards Catalog
    Last Updated On: January 6, 2016 USP Reference Standards Catalog Catalog # Description Current Lot Previous Lot CAS # NDC # Unit Price Special Restriction 1000408 Abacavir Sulfate R028L0 F1L487 (12/16) 188062-50-2 $222.00 (200 mg) 1000419 Abacavir Sulfate F0G248 188062-50-2 $692.00 Racemic (20 mg) (4-[2-amino-6-(cyclo propylamino)-9H-pur in-9yl]-2-cyclopenten e-1-methanol sulfate (2:1)) 1000420 Abacavir Related F1L311 F0H284 (10/13) 124752-25-6 $692.00 Compound A (20 mg) ([4-(2,6-diamino-9H- purin-9-yl)cyclopent- 2-enyl]methanol) 1000437 Abacavir Related F0M143 N/A $692.00 Compound D (20 mg) (N6-Cyclopropyl-9-{( 1R,4S)-4-[(2,5-diami no-6-chlorpyrimidin- 4-yloxy)methyl] cyclopent-2-enyl}-9H -purine-2,6-diamine) 1000441 Abacavir Related F1L318 F0H283 (10/13) N/A $692.00 Compound B (20 mg) ([4-(2,5-diamino-6-c Page 1 Last Updated On: January 6, 2016 USP Reference Standards Catalog Catalog # Description Current Lot Previous Lot CAS # NDC # Unit Price Special Restriction hloropyrimidin-4-yla mino)cyclopent-2-en yl]methanol) 1000452 Abacavir Related F1L322 F0H285 (09/13) 172015-79-1 $692.00 Compound C (20 mg) ([(1S,4R)-4-(2-amino -6-chloro-9H-purin-9 -yl)cyclopent-2-enyl] methanol hydrochloride) 1000485 Abacavir Related R039P0 F0J094 (11/16) N/A $692.00 Compounds Mixture (15 mg) 1000496 Abacavir F0J102 N/A $692.00 Stereoisomers Mixture (15 mg) 1000500 Abacavir System F0J097 N/A $692.00 Suitability Mixture (15 mg) 1000521 Acarbose (200 mg) F0M160 56180-94-0 $222.00 (COLD SHIPMENT REQUIRED) 1000532 Acarbose System F0L204 N/A $692.00 Suitability
    [Show full text]
  • Comparative Genomics of the Major Parasitic Worms
    Comparative genomics of the major parasitic worms International Helminth Genomes Consortium Supplementary Information Introduction ............................................................................................................................... 4 Contributions from Consortium members ..................................................................................... 5 Methods .................................................................................................................................... 6 1 Sample collection and preparation ................................................................................................................. 6 2.1 Data production, Wellcome Trust Sanger Institute (WTSI) ........................................................................ 12 DNA template preparation and sequencing................................................................................................. 12 Genome assembly ........................................................................................................................................ 13 Assembly QC ................................................................................................................................................. 14 Gene prediction ............................................................................................................................................ 15 Contamination screening ............................................................................................................................
    [Show full text]
  • I Comparative Activity of Anthelmintic
    Retour au menu Comparative activity of anthelmintic drugs, mebendazole, praziquantel and albendazole against Hymenolepis M. Gala1 ’ diminufa in experimentally infected S. R. Chin ’ Irats GALAL (MT), CHIN (S. R.). Comparaison de l’action de différents CAVIER and ROSSIGNOL (3) studied the taenicidal anthelminttuques (mébendazole, praziquantel et albendazole) contre properties of albendazole, mebendazole, niclosamide Hymenoleph diminuta chez des rats expérimentalement Infectés. Rev. Elev. Méd. vét. Pays trop., 1987, 40 (2) : 147-150. and praziquantel in experimentally infected mice and found that praziquantel and niclosamide have similar Des rats expérimentalement infectés avec If. diminufa ont été traités par voie orale avec trois anthelminthiques, administrés soit en dose taenicidal propet-ties. unique, soit en tiers de dose 3 jours consécutifs. Le praziquantel (250 mgkg ou 83 mg/k&j 3 fois) et I’alhendazole (800 mgkg ou Now are reported the comparative efficacy of meben- 167 mgkg/j 3 fois) ont totalement éliminé les vers, alors que le dazole, praziquantel and albendazole against experi- mébendazole (500 rng/kg- - ou 167 mg/kg/i- -. 3 fois) ne les a aue oartielle- mental infection of rats with H. diminuta, using single ment éliminés, avec une efficacité de 76 p. 160. Parmi ces j anthel- and divided oral doses for 3 consecutive days, 30 days mlnthlques, il n’a pas été relevé de différence signiiïcative d’efkacité entre les différents dosages pour chaque traitement. Aucune toxicité after infection. n’est apparue chez les rats traités. Mots CES : Rat - Helminthosc - Hymenolepis diminuta - Anthelminthique - Mébendazole - Prazi- quantel - Albendazole - Infection expérimentale. MATERIALS AND METHODS INTRODUCTION Definitive and intermediate hosts Albino rats (Rattus norvegicus) of both sexes and H.
    [Show full text]
  • Etude Rétrospective Des Déclarations D'effets Indésirables Graves Lors D
    Etude rétrospective des déclarations d’effets indésirables graves lors d’utilisation d’antiparasitaires externes chez le chat et le chien Kim Schumacher To cite this version: Kim Schumacher. Etude rétrospective des déclarations d’effets indésirables graves lors d’utilisation d’antiparasitaires externes chez le chat et le chien. Médecine vétérinaire et santé animale. Université Paris-Est Créteil Val de Marne (UPEC); École nationale vétérinaire d’Alfort, 2016. Français. tel- 01874183 HAL Id: tel-01874183 https://tel.archives-ouvertes.fr/tel-01874183 Submitted on 14 Sep 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. ÉCOLE NATIONALE VÉTÉRINAIRE D’ALFORT Année 2016 ÉTUDE RÉTROSPECTIVE DES DÉCLARATIONS D’EFFETS INDÉSIRABLES GRAVES LORS D’UTILISATION D’ANTIPARASITAIRES EXTERNES CHEZ LE CHAT ET LE CHIEN THÈSE Pour le DOCTORAT VÉTÉRINAIRE Présentée et soutenue publiquement devant LA FACULTÉ DE MÉDECINE DE CRÉTEIL le…………… par Kim Charlotte Amédée SCHUHMACHER Née le 4 décembre 1991 à Vélizy-Villacoublay (Yvelines) JURY Président : Pr. Professeur à la Faculté de Médecine de CRÉTEIL Membres Directeur : M. PERROT Sébastien Maître de conférences en Pharmacologie à l’ENVA Assesseur : Mme DARMON Céline Maître de conférences en Parasitologie à l’ENVA REMERCIEMENTS Au Professeur de la Faculté de médecine de Créteil, Qui nous a fait l’honneur d’accepter la présidence de notre jury de thèse, Hommage respectueux.
    [Show full text]
  • Redalyc.Determination of Niclosamide and Its Metabolites in Liver And
    Acta Scientiae Veterinariae ISSN: 1678-0345 [email protected] Universidade Federal do Rio Grande do Sul Brasil Kartalovic, Brankica; Pucarevic, Mira; Markovic, Zoran; Stankovic, Marko; Novakov, Nikolina; Pelic, Milos; Cirkovic, Miroslav Determination of Niclosamide and its Metabolites in Liver and Muscles of Common Carp (Cyprinus carpio) Fingerlings Acta Scientiae Veterinariae, vol. 45, 2017, pp. 1-6 Universidade Federal do Rio Grande do Sul Porto Alegre, Brasil Available in: http://www.redalyc.org/articulo.oa?id=289053641022 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Acta Scientiae Veterinariae, 2017. 45: 1490. RESEARCH ARTICLE ISSN 1679-9216 Pub. 1490 Determination of Niclosamide and its Metabolites in Liver and Muscles of Common Carp (Cyprinus carpio) Fingerlings Brankica Kartalović1 , Mira Pucarević2, Zoran Marković3, Marko Stanković3, Nikolina Novakov4, Milos Pelić1 & Miroslav Ćirković1 ABSTRACT Background: Niclosamide is a medication used to treat tapeworm infestation in animals and humans. It is also lampricide and molluscicide, and can be used in in agriculture as a pesticide. In the treatment of parasitic diseases in fish, niclosamide can be used as bath or mixed with the feed. Its most important use in common carp (Cyprinus carpio) is for the treatment of Bothriocephalus acheilognathi, which is a very common parasite in this fish species. The aim of this study was to de- termine the concentrations of niclosamide (NIC) and its metabolite 2-chloro 4-nitro aniline (CNA) and 5-chloro salycilic acid (CSA) in the liver and muscles of common carp fingerlings.
    [Show full text]
  • Download Brochure
    US Tape & Label Proof 4 inches Mild, transient hypersensitivity reactions, such as labored breathing, vomiting, hypersalivation, and lethargy have been noted in some dogs treated with milbemycin oxime carrying a high number of circulating microfilariae. These reactions are presumably caused by release of protein from dead or dying microfilariae. Do not use in puppies less than six weeks of age. Do not use in dogs or puppies less than two pounds of body weight. The safety of SENTINEL® SPECTRUM® Chews has not been evaluated in dogs used for breeding or in lactating females. Studies have been performed with milbemycin oxime and lufenuron alone (see ANIMAL SAFETY). es h Adverse Reactions: The following adverse reactions have been reported in dogs after administration of c milbemycin oxime, lufenuron, or praziquantel: vomiting, depression/lethargy, pruritus, urticaria, diarrhea, anorexia, n US Tape & Label Proof skin congestion, ataxia, convulsions, salivation, and weakness. To report suspected adverse drug events, contact Merck Animal Health at 1-800-224-5381. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or 2.25 i http://www.fda.gov/reportanimalae. 4 inches For technical assistance, call Merck Animal Health at 1-800-224-5318. Information for Owner or Person Treating Animal: Echinococcus multilocularis and Echinococcus granulosus are tapeworms found in wild canids and domestic dogs. E. multilocularis and E. granulosus can infect humans and cause serious disease (alveolar hydatid disease and hydatid disease, respectively). Owners of dogs living in areas where E. multilocularis or E. granulosus are endemic should be instructed on how to minimize their risk of exposure to these parasites, as well as their dog’s risk of exposure.
    [Show full text]
  • Pharmacopoeial Reference Standards and Their Current Lot Numbers EP, EPISA, ICRS, BP July 2019
    Pharmacopoeial reference standards and their current lot numbers EP, EPISA, ICRS, BP July 2019 Mikromol Follow LGC on LinkedIn Dear user, This catalogue includes all pharmacopoeial reference materials from EP, EPISA, ICRS and BP available at LGC, as well as their current lot numbers. We update the catalogue on a monthly basis so that you can use the lot numbers to easily track the expiry dates of your stocked reference materials. We took the lot information from actual data from pharmacopoeias, correct at the time of production. We retained all spelling and information as provided by the pharmacopoeias. The list was compiled with caution, however, errors in this list may be possible, and LGC is not responsible for any consequences as a result of these errors, may it be errors in the original Pharmacopoeial data, or from LGC during compilation of this list. For any questions or orders please contact your local LGC office. You will find all contact details on the last page of this list. Alternatively, you can browse and buy pharmaceutical reference materials online at lgcstandards.com/mikromol. Stay connected via LinkedIn (LGC Mikromol) or Twitter @LGCMikromol. Kind regards Your LGC Standards Team LGC, Queens Road, Teddington, Middlesex, TW11 0LY, United Kingdom Tel: +44 (0)20 8943 8480 Fax: +44 (0)20 8943 7554 E-mail: [email protected] European Pharmacopoeia (EP) Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001552 Abacavir for peak identification 1 10 mg EPY0001551 Abacavir for system suitability 1
    [Show full text]
  • C.8. C.9. /S.II G Courses Prof
    Cursuri Romeo T. Cristina T. Romeo Cursuri C.8. C.9. Image soure: ®® http://www.colonlove.com/assets/images/Parasites.jpg /S.II Antiparasitic medication Courses Prof. Romeo T. Cristina® Introduction thethetheantiparasitic therapy isisis based ononon aaa large number ofofof substances, thethethe majority ofofof them areareare syntheticsynthetic.... Most antiparasitic drugs affect thethethe neuromuscular system ofofof thethethe parasite bybyby blocking thethethe neuromuscular junctions, with thethethefinal result ofofof: of ::: paralysis, death and disposaldisposal.... itititisisis known that helminths have also aaa reversible paralysis, sososothat ififif they areareare not eliminated ininin due time, they will recoverrecover. ... Courses Prof. Romeo T. Cristina® The substances ofofof tehthe tehorganophosphorus group eraare era knownforfor fortheir effectiveness onon onboth helminths and ectoparasitesaerare aergrafted ininin their useuse usebybyby relative high toxicity ... Their mechanism isisis based onon on blocking ehtthe eht acetylcholinesterase enzyme, which isisis tehthe tehenzyme necessaryforfor the forthe thehydrolysis ofofof acetylcholineacetylcholine. ... ByBy Byblocking this enzyme, tehthe tehmediator can onno onlongerbebe be releasedreleased,teh,,, the tehstimulus remains open resulting htethe hte exhaustion and death theofofof the theparasiteparasite. ... Courses Prof. Romeo T. Cristina® Other substances interfere with thethethe processes ofofofATP phosphorylationphosphorylation.... dichlorophenol, niclosamide, benzimidazoles
    [Show full text]